An advisory panel to the FDA has recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.
NEW YORK CITY—Repetitive transcranial magnetic stimulation may help improve refractory depression in patients with borderline personality disorder, says research presented at the American Psychiatric Association’s annual meeting.
NEW YORK CITY—Using pharmacogenomic testing to guide medication selection for patients with depression improved rates of response and remission, researchers reported at the American Psychiatric Association’s annual meeting.
NEW YORK CITY—Esketamine nasal spray reduced symptoms in patients with treatment-resistant depression in two Phase 3 clinical trials, but the decrease was statistically significant in only one of the trials.
NEW YORK CITY—Early evidence suggests the tuberculosis drug D-cycloserine may ease treatment-resistant depression and supports further trials on its efficacy as a novel antidepressant, a research review found.
NEW YORK CITY—Exercise should be prescribed—not just recommended—for patients with depression, using specific techniques to boost patient buy-in and adherence, a team of military clinicians said at the American Psychiatric Association’s annual meeting.